These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 7831676

  • 1. Cost effectiveness and ease of administration of low molecular weight heparin in deep vein thrombosis.
    Teo CP, Lim HL, Kueh YK.
    Thromb Haemost; 1994 Aug; 72(2):328-9. PubMed ID: 7831676
    [No Abstract] [Full Text] [Related]

  • 2. [Evaluation of hospital cost of six days of treatment of deep venous thrombosis. Comparison of subcutaneous nadroparin and intravenous heparin in 40 patients].
    Lévesque H, Cailleux N, Vasse D, Legallicier B, Moore N, Borg JY, Hantute N, Thuillez C, Courtois H.
    Therapie; 1994 Aug; 49(2):101-5. PubMed ID: 7817331
    [Abstract] [Full Text] [Related]

  • 3. Economic evaluation of the use of nadroparin in the treatment of deep-vein thrombosis in Switzerland.
    Lloyd AC, Aitken JA, Hoffmeyer UK, Kelso EJ, Wakerly EC, Barber ND.
    Ann Pharmacother; 1997 Aug; 31(7-8):842-6. PubMed ID: 9220041
    [Abstract] [Full Text] [Related]

  • 4. [Low molecular weight heparins. No increase of the cost of treatment of deep venous thrombosis].
    Levesque H, Cailleux N, Courtois H.
    Presse Med; 1997 Aug; 23(17):816. PubMed ID: 8078843
    [No Abstract] [Full Text] [Related]

  • 5. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
    Hull RD, Raskob GE, Pineo GF, Feldstein W, Rosenbloom D, Gafni A, Green D, Feinglass J, Trowbridge AA, Elliott CG.
    Arch Intern Med; 1997 Feb 10; 157(3):298-303. PubMed ID: 9040296
    [Abstract] [Full Text] [Related]

  • 6. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis.
    Stricker H, Marchetti O, Haeberli A, Mombelli G.
    Thromb Haemost; 1999 Oct 10; 82(4):1227-31. PubMed ID: 10544903
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Secondary prophylaxis with low molecular weight heparin: the dose?
    Horne MK.
    Thromb Haemost; 2001 Oct 10; 86(4):1129. PubMed ID: 11686343
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P, Laporte-Simitsidis S, Navarro C, Sié P, d'Azemar P, Necciari J, Duret JP, Gaud C, Decousus H, Boneu B.
    Thromb Haemost; 1998 Jun 10; 79(6):1162-5. PubMed ID: 9657442
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.
    Mismetti P, Mille D, Laporte S, Charlet V, Buchmüller-Cordier A, Jacquin JP, Fournel P, Dutrey-Dupagne C, Decousus H, CIP Study Group.
    Haematologica; 2003 Jan 10; 88(1):67-73. PubMed ID: 12551829
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.